Vaxcyte, Inc. (PCVX) shareholders
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$64.69−3.93 (-5.73%)
Close on Nov 12, 2026Market cap $9.63BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
167M of 149M shares
Institutional holders
331
50 new, 50 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 58 sales
Net sold $12.74M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.40%) | 20,798,907 | 14.40% | 13G (passive) amendment | Jun 30, 2026 |
| JANUS HENDERSON GROUP Ltd. | 18,040,375 | 12.10% | 13G (passive) amendment | Jul 31, 2026 |
| Janus Henderson Group PLC | 16,575,875 | 11.50% | 13G (passive) amendment | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (11.40%) | 16,451,061 | 11.40% | 13G (passive) amendment | Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 14,312,368 | 9.60% | 13G (passive) amendment | Sep 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (8.90%), Peter Kolchinsky (8.90%) and 1 more | 12,974,599 | 8.90% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 12,964,491 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 9,825,638 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 7,252,053 | 5.03% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PCVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 20,852,907 | 14.01% | $1.21B | +4,360,046 | 0.05% |
| Jupiter Topco LLC | 17,965,847 | 12.07% | $1.04B | New | 0.43% |
| T. Rowe Price Investment Management, Inc. | 12,207,450 | 8.20% | $709.62M | +81,433 | 0.47% |
| BlackRock, Inc. | 12,068,129 | 8.11% | $701.52M | +1,096,313 | 0.01% |
| Ra Capital Management, L.P. | 11,474,599 | 7.71% | $667.02M | – | 5.80% |
| Wellington Management Group Llp | 7,001,565 | 4.71% | $407.00M | +1,386,968 | 0.07% |
| Vanguard Portfolio Management LLC | 6,593,551 | 4.43% | $383.28M | +314,006 | 0.02% |
| Vanguard Capital Management LLC | 6,348,679 | 4.27% | $369.05M | +81,978 | 0.01% |
| State Street Corp | 5,351,698 | 3.60% | $311.09M | +911,179 | 0.01% |
| Deep Track Capital, LP | 4,300,000 | 2.89% | $249.96M | – | 3.64% |
| Geode Capital Management, LLC | 3,459,363 | 2.32% | $201.13M | +258,080 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 2,988,999 | 2.01% | $173.75M | +2,012,570 | 0.02% |
| Kynam Capital Management, LP | 2,922,335 | 1.96% | $169.88M | – | 9.39% |
| Westfield Capital Management Co LP | 2,472,428 | 1.66% | $143.72M | −1,173,710 | 0.47% |
| Caligan Partners LP | 2,188,636 | 1.47% | $127.23M | +127,917 | 5.99% |
| Paradigm Biocapital Advisors LP | 2,127,852 | 1.43% | $123.69M | −2,665,168 | 2.32% |
| Bellevue Group AG | 1,971,935 | 1.33% | $114.63M | +781,238 | 2.41% |
| D. E. Shaw & Co., Inc. | 1,901,872 | 1.28% | $110.56M | −963,446 | 0.05% |
| Maverick Capital Ltd | 1,613,242 | 1.08% | $93.78M | +235,504 | 0.83% |
| Charles Schwab Investment Management Inc | 1,464,812 | 0.98% | $85.15M | +60,864 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 331 | 167M | 100.0% | 50 / 132 | 101 / 50 | 38M | 17M |
| Q1 2026 | 336 | 163M | 100.0% | 71 / 128 | 82 / 25 | 36M | 15M |
| Q4 2025 | 295 | 154M | 100.0% | 60 / 95 | 107 / 45 | 27M | 15M |
| Q3 2025 | 286 | 143M | 96.0% | 40 / 100 | 104 / 43 | 13M | 19M |
| Q2 2025 | 294 | 148M | 99.6% | 57 / 132 | 76 / 75 | 26M | 24M |
| Q1 2025 | 315 | 146M | 98.2% | 59 / 128 | 98 / 63 | 17M | 11M |
| Q4 2024 | 323 | 141M | 94.6% | 62 / 139 | 90 / 62 | 18M | 15M |
| Q3 2024 | 329 | 138M | 92.7% | 86 / 129 | 88 / 20 | 30M | 6M |
| Q2 2024 | 265 | 124M | 83.4% | 38 / 116 | 79 / 23 | 9M | 6M |
| Q1 2024 | 251 | 122M | 81.7% | 48 / 103 | 76 / 18 | 23M | 5M |
| Q4 2023 | 223 | 104M | 70.2% | 37 / 87 | 68 / 16 | 9M | 6M |
| Q3 2023 | 202 | 101M | 68.1% | 24 / 86 | 58 / 16 | 7M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
428 funds held PCVX in Q2 2026, 31% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PCVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,587,918 | 3.08% | $266.70M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 4,007,229 | 2.69% | $232.94M | 0.33% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,392,214 | 2.28% | $197.19M | 0.24% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,312,950 | 2.23% | $192.58M | 0.10% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 3,034,105 | 2.04% | $155.95M | 0.06% | May 31, 2026 |
| Janus Henderson Forty Fund | 2,676,774 | 1.80% | $155.60M | 0.65% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,340,735 | 1.57% | $126.59M | 0.33% | Jul 31, 2026 |
| Janus Henderson Enterprise Fund | 2,269,870 | 1.53% | $131.95M | 0.59% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,192,112 | 1.47% | $127.43M | 1.19% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,911,818 | 1.28% | $111.13M | 0.24% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,507,794 | 1.01% | $87.65M | 0.09% | Jun 30, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 1,477,243 | 0.99% | $75.93M | 0.22% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,440,296 | 0.97% | $77.89M | 0.23% | Jul 31, 2026 |
| Vanguard Explorer Fund | 1,318,149 | 0.89% | $71.29M | 0.32% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,302,720 | 0.88% | $75.73M | 0.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER, Director | 563,117 | 0.38% | Sep 9, 2026 |
| Elvia Cowan | SVP, Finance & CAO | 27,860 | 0.02% | Nov 4, 2026 |
| Jim Wassil | EVP, Chief Scientific Ofc, COO | 145,435 | 0.10% | Nov 4, 2026 |
| Andrew Guggenhime | PRESIDENT AND CFO | 157,166 | 0.11% | Sep 9, 2026 |
| Luis Jodar | Chief Medical Officer | 52,632 | 0.04% | Sep 9, 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | 68,085 | 0.05% | Sep 9, 2026 |
| Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | 41,732 | 0.03% | Mar 7, 2025 |
| John Markels | Director | 0 | – | Jul 16, 2026 |
| Moncef Slaoui | Director | 0 | – | Jun 23, 2026 |
| Jacks Lee | Director | 6,856 | 0.00% | Jun 16, 2026 |
| Anne S. Drapeau | Director | 12,481 | 0.01% | Jun 16, 2026 |
| Olivier Brandicourt | Director | 4,699 | 0.00% | Jun 16, 2026 |
| Heath Lukatch | Director | 19,481 | 0.01% | Jun 16, 2026 |
| Halley E. Gilbert | Director | 12,481 | 0.01% | Jun 16, 2026 |
| Carlos V. Paya | Director | 12,481 | 0.01% | Jun 16, 2026 |
| John Furey | Director | 5,306 | 0.00% | Jun 16, 2026 |
| Teri Loxam | Director | 12,481 | 0.01% | Jun 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Elvia Cowan SVP, Finance & CAO | Nov 2, 2026 | Sale(10b5-1 plan) | −586 | $61.55 | $36.07K | 27,860 |
| Elvia Cowan SVP, Finance & CAO | Nov 2, 2026 | Sale(10b5-1 plan) | −2,414 | $60.77 | $146.69K | 28,446 |
| Elvia Cowan SVP, Finance & CAO | Nov 2, 2026 | Option exercise | +3,000 | $25.92 | $77.76K | 30,860 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Nov 2, 2026 | Sale(10b5-1 plan) | −343 | $61.57 | $21.12K | 145,435 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Nov 2, 2026 | Sale(10b5-1 plan) | −1,907 | $60.78 | $115.91K | 145,778 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Nov 2, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 147,685 |
| Elvia Cowan SVP, Finance & CAO | Oct 5, 2026 | Sale(10b5-1 plan) | −19,000 | $86.74 | $1.65M | 27,860 |
| Elvia Cowan SVP, Finance & CAO | Oct 5, 2026 | Option exercise | +19,000 | $25.92 | $492.48K | 46,860 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Oct 5, 2026 | Sale(10b5-1 plan) | −18,000 | $86.74 | $1.56M | 145,435 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Oct 5, 2026 | Option exercise | +18,000 | $5.35 | $96.30K | 163,435 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Oct 1, 2026 | Sale(10b5-1 plan) | −95 | $57.09 | $5.42K | 145,435 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Oct 1, 2026 | Sale(10b5-1 plan) | −2,155 | $56.65 | $122.09K | 145,530 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Oct 1, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 147,685 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 9, 2026 | Sale(10b5-1 plan) | −1,334 | $59.52 | $79.40K | 145,435 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Sep 8, 2026 | Tax withholding | −17,056 | $60.36 | $1.03M | 429,902 |
| Andrew Guggenhime PRESIDENT AND CFO | Sep 8, 2026 | Tax withholding | −7,155 | $60.36 | $431.88K | 95,316 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Sep 8, 2026 | Tax withholding | −7,651 | $60.36 | $461.81K | 68,085 |
| Elvia Cowan SVP, Finance & CAO | Sep 8, 2026 | Tax withholding | −1,327 | $60.36 | $80.10K | 27,860 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 8, 2026 | Tax withholding | −5,459 | $60.36 | $329.51K | 146,769 |
| Luis Jodar Chief Medical Officer | Sep 4, 2026 | Award | +52,632 | – | – | 52,632 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 4, 2026 | Sale(10b5-1 plan) | −1,381 | $61.16 | $84.46K | 152,228 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 2, 2026 | Tax withholding | −1,432 | $61.58 | $88.18K | 153,609 |
| Andrew Guggenhime PRESIDENT AND CFO | Sep 2, 2026 | Tax withholding | −1,432 | $61.58 | $88.18K | 102,471 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Tax withholding | −3,427 | $61.58 | $211.03K | 446,958 |
| Elvia Cowan SVP, Finance & CAO | Sep 2, 2026 | Tax withholding | −326 | $61.58 | $20.08K | 29,187 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Sep 2, 2026 | Tax withholding | −659 | $61.58 | $40.58K | 75,736 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −924 | $60.96 | $56.33K | 155,344 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −713 | $61.48 | $43.84K | 156,268 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −1,537 | $60.89 | $93.59K | 156,981 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 158,518 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −303 | $61.42 | $18.61K | 155,041 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 31, 2026 | Tax withholding | −1,273 | $60.74 | $77.32K | 156,268 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 31, 2026 | Tax withholding | −1,273 | $60.74 | $77.32K | 103,903 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Aug 31, 2026 | Tax withholding | −2,862 | $60.74 | $173.84K | 450,385 |
| Elvia Cowan SVP, Finance & CAO | Aug 31, 2026 | Tax withholding | −243 | $60.74 | $14.76K | 29,513 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 31, 2026 | Tax withholding | −361 | $60.74 | $21.93K | 76,395 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 5, 2026 | Option exercise | +17,000 | $24.79 | $421.43K | 93,756 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −17,000 | $55.00 | $935.00K | 76,756 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Sale(10b5-1 plan) | −3,044 | $54.18 | $164.92K | 105,176 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Option exercise | +10,000 | $5.35 | $53.50K | 115,176 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Sale(10b5-1 plan) | −6,956 | $53.76 | $373.95K | 108,220 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,389 | $54.09 | $75.13K | 157,541 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −861 | $53.50 | $46.06K | 158,930 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 159,791 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −378 | $55.91 | $21.13K | 133,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −11,783 | $55.52 | $654.19K | 457,662 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −4,415 | $55.93 | $246.93K | 453,247 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −756 | $55.52 | $41.97K | 133,459 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −244 | $55.96 | $13.65K | 133,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −622 | $55.54 | $34.55K | 133,593 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Option exercise | +16,198 | $2.03 | $32.88K | 469,445 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Sale(10b5-1 plan) | −7,913 | $57.16 | $452.31K | 106,482 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Sale(10b5-1 plan) | −2,087 | $57.76 | $120.55K | 104,395 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Option exercise | +10,000 | $5.35 | $53.50K | 114,395 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −1,788 | $56.03 | $100.18K | 157,222 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −456 | $57.47 | $26.21K | 156,766 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −6 | $57.82 | $347 | 156,760 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Option exercise | +516 | $5.35 | $2.76K | 159,010 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −332 | $55.99 | $18.59K | 134,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −356 | $55.23 | $19.66K | 134,547 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
10.40%
15M shares short
Days to cover
6.7
At 2M shares a day
Change since last report
+5.0%
From 15M shares
Short volume, 20 days
72.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vaxcyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 461,970 shares on Oct 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jim Wassil Officer | Nov 2, 2026 | 2,250 | $139.23K | Nov 2, 2026 | Exercise of stock option |
| Elvia Cowan Officer | Nov 2, 2026 | 3,000 | $185.64K | Nov 2, 2026 | Exercise of Stock Options |
| Elvia Cowan Officer | Oct 5, 2026 | 19,000 | $1.65M | Oct 5, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Oct 5, 2026 | 18,000 | $1.56M | Oct 5, 2026 | Exercise of stock option |
| Jim Wassil Officer | Oct 1, 2026 | 2,250 | $127.64K | Oct 1, 2026 | Exercise of stock option |
| Jim Wassil Officer | Sep 9, 2026 | 1,334 | $80.03K | Sep 9, 2026 | RSU Vest |
| Jim Wassil Officer | Sep 4, 2026 | 1,381 | $82.49K | Sep 4, 2026 | RSU Vest |
| Jim Wassil Officer | Sep 1, 2026 | 3,477 | $209.63K | Sep 1, 2026 | RSU Vest |
| Harpreet S. Dhaliwal Officer | Aug 5, 2026 | 17,000 | $935.00K | Aug 5, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Aug 3, 2026 | 2,250 | $121.48K | Aug 3, 2026 | Exercise of stock options |
| Andrew Guggenhime Officer | Aug 3, 2026 | 10,000 | $539.90K | Aug 3, 2026 | Exercise of Stock Options |
| Grant Pickering Officer, Director | Jul 27, 2026 | 18,198 | $996.70K | Jul 27, 2026 | Exercise of Stock Options |
| Andrew Guggenhime Officer | Jul 6, 2026 | 10,000 | $577.60K | Jul 6, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Jul 1, 2026 | 2,250 | $130.79K | Jul 1, 2026 | RSU Vest |
| Grant Pickering Officer, Director | Jun 26, 2026 | 24,237 | $1.30M | Jun 26, 2026 | RSU Vest |
See a number that looks wrong?